Stockreport

Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cance...

Dare Bioscience, Inc.  (DARE) 
Last dare bioscience, inc. earnings: 8/14 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.darebioscience.com/investor-relations
PDF SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Dare´ Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’ [Read more]